vs
博士伦健康（BHC）与美盛公司（MOS）财务数据对比。点击上方公司名可切换其他公司
美盛公司的季度营收约是博士伦健康的1.1倍（$3.0B vs $2.8B），博士伦健康净利率更高（-3.7% vs -17.5%，领先13.8%），博士伦健康同比增速更快（9.3% vs 5.6%），博士伦健康自由现金流更多（$403.0M vs $-405.7M），过去两年博士伦健康的营收复合增速更高（14.0% vs 5.3%）
博士伦健康公司（Bausch Health）是一家业务多元化的北美跨国制药企业，全球总部位于加拿大魁北克省拉瓦尔，美国总部设在新泽西州布里奇沃特。公司专注于胃肠病、肝病、神经科、皮肤科、牙科、医疗美容等领域的药物研发、生产及销售，同时提供品牌药和仿制药产品，业务覆盖全球市场。
美盛公司（The Mosaic Company）是总部位于美国佛罗里达州坦帕的化工企业，主营磷矿、钾矿开采及尿素采集，依托多元国际分销网络和旗下肥料业务板块生产销售农用肥料，是美国规模最大的钾肥、磷肥生产商。
BHC vs MOS — 直观对比
营收规模更大
MOS
是对方的1.1倍
$2.8B
营收增速更快
BHC
高出3.7%
5.6%
净利率更高
BHC
高出13.8%
-17.5%
自由现金流更多
BHC
多$808.7M
$-405.7M
两年增速更快
BHC
近两年复合增速
5.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.8B | $3.0B |
| 净利润 | $-103.0M | $-519.5M |
| 毛利率 | — | 11.5% |
| 营业利润率 | 17.0% | -3.4% |
| 净利率 | -3.7% | -17.5% |
| 营收同比 | 9.3% | 5.6% |
| 净利润同比 | -205.1% | -407.4% |
| 每股收益（稀释后） | $-0.30 | $-1.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BHCMOS
| Q4 25 | $2.8B | $3.0B | ||
| Q3 25 | $2.7B | $3.5B | ||
| Q2 25 | $2.5B | $3.0B | ||
| Q1 25 | $2.3B | $2.6B | ||
| Q4 24 | $2.6B | $2.8B | ||
| Q3 24 | $2.5B | $2.8B | ||
| Q2 24 | $2.4B | $2.8B | ||
| Q1 24 | $2.2B | $2.7B |
净利润BHCMOS
| Q4 25 | $-103.0M | $-519.5M | ||
| Q3 25 | $179.0M | $411.4M | ||
| Q2 25 | $148.0M | $410.7M | ||
| Q1 25 | $-58.0M | $238.1M | ||
| Q4 24 | $98.0M | $169.0M | ||
| Q3 24 | $-85.0M | $122.2M | ||
| Q2 24 | $10.0M | $-161.5M | ||
| Q1 24 | $-64.0M | $45.2M |
毛利率BHCMOS
| Q4 25 | — | 11.5% | ||
| Q3 25 | — | 16.0% | ||
| Q2 25 | — | 17.3% | ||
| Q1 25 | — | 18.6% | ||
| Q4 24 | — | 10.7% | ||
| Q3 24 | — | 14.8% | ||
| Q2 24 | — | 14.0% | ||
| Q1 24 | — | 14.9% |
营业利润率BHCMOS
| Q4 25 | 17.0% | -3.4% | ||
| Q3 25 | 23.1% | 9.8% | ||
| Q2 25 | 17.5% | 8.1% | ||
| Q1 25 | 12.2% | 12.9% | ||
| Q4 24 | 21.8% | 3.5% | ||
| Q3 24 | 12.7% | 4.1% | ||
| Q2 24 | 16.2% | 8.3% | ||
| Q1 24 | 13.1% | 6.5% |
净利率BHCMOS
| Q4 25 | -3.7% | -17.5% | ||
| Q3 25 | 6.7% | 11.9% | ||
| Q2 25 | 5.8% | 13.7% | ||
| Q1 25 | -2.6% | 9.1% | ||
| Q4 24 | 3.8% | 6.0% | ||
| Q3 24 | -3.4% | 4.3% | ||
| Q2 24 | 0.4% | -5.7% | ||
| Q1 24 | -3.0% | 1.7% |
每股收益（稀释后）BHCMOS
| Q4 25 | $-0.30 | $-1.63 | ||
| Q3 25 | $0.48 | $1.29 | ||
| Q2 25 | $0.40 | $1.29 | ||
| Q1 25 | $-0.16 | $0.75 | ||
| Q4 24 | $0.24 | $0.53 | ||
| Q3 24 | $-0.23 | $0.38 | ||
| Q2 24 | $0.03 | $-0.50 | ||
| Q1 24 | $-0.17 | $0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $276.6M |
| 总债务越低越好 | $20.8B | $4.3B |
| 股东权益账面价值 | $-554.0M | $12.1B |
| 总资产 | $26.4B | $24.5B |
| 负债/权益比越低杠杆越低 | — | 0.35× |
8季度趋势，按日历期对齐
现金及短期投资BHCMOS
| Q4 25 | $1.3B | $276.6M | ||
| Q3 25 | $1.3B | $153.3M | ||
| Q2 25 | $1.7B | $286.2M | ||
| Q1 25 | $1.1B | $259.2M | ||
| Q4 24 | $1.2B | $272.8M | ||
| Q3 24 | $719.0M | $301.6M | ||
| Q2 24 | $595.0M | $322.0M | ||
| Q1 24 | $733.0M | $336.7M |
总债务BHCMOS
| Q4 25 | $20.8B | $4.3B | ||
| Q3 25 | $21.0B | $3.4B | ||
| Q2 25 | $21.7B | $3.3B | ||
| Q1 25 | $21.5B | $3.3B | ||
| Q4 24 | $21.6B | $3.3B | ||
| Q3 24 | $21.5B | $3.2B | ||
| Q2 24 | $21.7B | $3.2B | ||
| Q1 24 | $22.1B | $3.2B |
股东权益BHCMOS
| Q4 25 | $-554.0M | $12.1B | ||
| Q3 25 | $-565.0M | $12.8B | ||
| Q2 25 | $-764.0M | $12.4B | ||
| Q1 25 | $-1.2B | $11.8B | ||
| Q4 24 | $-1.3B | $11.5B | ||
| Q3 24 | $-1.2B | $11.8B | ||
| Q2 24 | $-1.2B | $11.7B | ||
| Q1 24 | $-1.1B | $12.0B |
总资产BHCMOS
| Q4 25 | $26.4B | $24.5B | ||
| Q3 25 | $26.8B | $24.7B | ||
| Q2 25 | $27.3B | $24.3B | ||
| Q1 25 | $26.4B | $23.2B | ||
| Q4 24 | $26.5B | $22.9B | ||
| Q3 24 | $26.5B | $23.3B | ||
| Q2 24 | $26.5B | $22.6B | ||
| Q1 24 | $26.9B | $22.9B |
负债/权益比BHCMOS
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 0.28× | ||
| Q4 24 | — | 0.29× | ||
| Q3 24 | — | 0.27× | ||
| Q2 24 | — | 0.27× | ||
| Q1 24 | — | 0.27× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $495.0M | $-56.1M |
| 自由现金流经营现金流 - 资本支出 | $403.0M | $-405.7M |
| 自由现金流率自由现金流/营收 | 14.4% | -13.6% |
| 资本支出强度资本支出/营收 | 3.3% | 11.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $1.0B | $-534.6M |
8季度趋势，按日历期对齐
经营现金流BHCMOS
| Q4 25 | $495.0M | $-56.1M | ||
| Q3 25 | $405.0M | $228.5M | ||
| Q2 25 | $289.0M | $609.5M | ||
| Q1 25 | $211.0M | $42.9M | ||
| Q4 24 | $601.0M | $219.3M | ||
| Q3 24 | $405.0M | $312.9M | ||
| Q2 24 | $380.0M | $847.0M | ||
| Q1 24 | $211.0M | $-80.0M |
自由现金流BHCMOS
| Q4 25 | $403.0M | $-405.7M | ||
| Q3 25 | $314.0M | $-135.9M | ||
| Q2 25 | $190.0M | $304.9M | ||
| Q1 25 | $96.0M | $-297.9M | ||
| Q4 24 | $495.0M | $-74.8M | ||
| Q3 24 | $334.0M | $72.1M | ||
| Q2 24 | $302.0M | $513.1M | ||
| Q1 24 | $129.0M | $-463.0M |
自由现金流率BHCMOS
| Q4 25 | 14.4% | -13.6% | ||
| Q3 25 | 11.7% | -3.9% | ||
| Q2 25 | 7.5% | 10.1% | ||
| Q1 25 | 4.2% | -11.4% | ||
| Q4 24 | 19.3% | -2.7% | ||
| Q3 24 | 13.3% | 2.6% | ||
| Q2 24 | 12.6% | 18.2% | ||
| Q1 24 | 6.0% | -17.3% |
资本支出强度BHCMOS
| Q4 25 | 3.3% | 11.8% | ||
| Q3 25 | 3.4% | 10.6% | ||
| Q2 25 | 3.9% | 10.1% | ||
| Q1 25 | 5.1% | 13.0% | ||
| Q4 24 | 4.1% | 10.4% | ||
| Q3 24 | 2.8% | 8.6% | ||
| Q2 24 | 3.2% | 11.9% | ||
| Q1 24 | 3.8% | 14.3% |
现金转化率BHCMOS
| Q4 25 | — | — | ||
| Q3 25 | 2.26× | 0.56× | ||
| Q2 25 | 1.95× | 1.48× | ||
| Q1 25 | — | 0.18× | ||
| Q4 24 | 6.13× | 1.30× | ||
| Q3 24 | — | 2.56× | ||
| Q2 24 | 38.00× | — | ||
| Q1 24 | — | -1.77× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
MOS
暂无分部数据
